Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
- 29 June 2022
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (4) , 374-376
Abstract
The value of variant-adapted vaccines that are capable of inducing a higher and broader immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at booster vaccination is currently being evaluated.1-4 We conducted a multicenter, randomized, single-blind trial to assess the immunogenicity and safety of two adjuvanted recombinant vaccines and the messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech) administered as a booster (ClinicalTrials.gov number, NCT05124171; EudraCT number, 2021-004550-33).Keywords
All Related Versions
Funding Information
- Ministry of Health and Solidarity
This publication has 4 references indexed in Scilit:
- Audio Interview: Do We Need New Covid-19 Vaccines?New England Journal of Medicine, 2022
- Homologous and Heterologous Covid-19 Booster VaccinationsNew England Journal of Medicine, 2022
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysisNature Medicine, 2021